Compare KALV & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALV | BLMN |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.2M | 569.7M |
| IPO Year | N/A | 2012 |
| Metric | KALV | BLMN |
|---|---|---|
| Price | $16.12 | $5.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $30.00 | $8.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 03-11-2026 | 02-25-2026 |
| Dividend Yield | N/A | ★ 7.54% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,426,000.00 | ★ $3,952,793,000.00 |
| Revenue This Year | N/A | $2.22 |
| Revenue Next Year | $204.16 | $0.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.72 |
| 52 Week Low | $8.74 | $5.86 |
| 52 Week High | $19.00 | $12.91 |
| Indicator | KALV | BLMN |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 34.81 |
| Support Level | $15.22 | $7.30 |
| Resistance Level | $16.16 | $6.86 |
| Average True Range (ATR) | 0.88 | 0.41 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 76.95 | 3.08 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabba's. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S., while restaurants operating outside the U.S. are included in the international segment.